Conclusions
CAD, T2D, improves coronary microvascular dysfunction
CAD
The present study provides evidence that treatment with SGLT-2i dapagliflozin significantly reduces EAT thickness and EAT glucose uptake in patients with T2D and stable CAD. The decrease in glucose extraction parallels the decrease in resting myocardial blood flow, and the improvement in myocardial flow reserve. We speculate that SGLT-2i treatment restores the anti-inflammatory properties of EAT, which improves coronary microvascular dysfunction, thus providing a potential explanation for the previously described improvement in myocardial flow reserve [